Redox regulation, NF-kappaB, and atrial fibrillation
- PMID: 19309257
- PMCID: PMC2819799
- DOI: 10.1089/ars.2009.2595
Redox regulation, NF-kappaB, and atrial fibrillation
Abstract
Atrial fibrillation (AF) is the most common clinically encountered abnormal heart beat. It is associated with an increased risk of stroke and symptoms of heart failure. Current therapies are directed toward controlling the rate of ventricular activation and preventing strokes through anticoagulation. Attempts at suppressing the arrhythmia are often ineffective, in part because the underlying pathogenesis is poorly understood. Recently, structural and electrical remodeling has been shown to occur during AF. These changes involve alterations in gene regulation and help perpetuate the arrhythmia. Some signals for remodeling are have been identified. Moreover, AF is associated with oxidative stress, and this redox imbalance may contribute to the altered gene regulation. One likely mediator of this change in transcriptional regulation is the redox sensitive transcription factor, nuclear factor-kappaB (NF-kappaB). Recently, NF-kappaB has been shown to downregulate transcription of the cardiac sodium channel in response to oxidative stress. NF-kappaB may contribute to the regulation of other ion channels, transcription factors, or splicing factors altered in AF and may represent a therapeutic target in AF management.
Figures





Similar articles
-
Redox control of cardiac remodeling in atrial fibrillation.Biochim Biophys Acta. 2015 Aug;1850(8):1555-65. doi: 10.1016/j.bbagen.2014.12.012. Epub 2014 Dec 13. Biochim Biophys Acta. 2015. PMID: 25513966 Review.
-
Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-α/NF-κB/TGF-β signal transduction pathway in alloxan-induced diabetic rabbits.J Cardiovasc Electrophysiol. 2015 Feb;26(2):211-22. doi: 10.1111/jce.12540. Epub 2014 Oct 17. J Cardiovasc Electrophysiol. 2015. PMID: 25199622
-
Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia.Exp Biol Med (Maywood). 2008 May;233(5):558-74. doi: 10.3181/0706-RM-155. Epub 2008 Mar 28. Exp Biol Med (Maywood). 2008. PMID: 18375832
-
Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-κB/HIF-1α regulatory axis and atrial remodeling.Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113403. doi: 10.1016/j.intimp.2024.113403. Epub 2024 Oct 21. Int Immunopharmacol. 2024. PMID: 39437485
-
Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation.Cardiovasc Res. 1999 May;42(2):298-308. doi: 10.1016/s0008-6363(99)00022-x. Cardiovasc Res. 1999. PMID: 10533568 Review.
Cited by
-
The Key Role of Uric Acid in Oxidative Stress, Inflammation, Fibrosis, Apoptosis, and Immunity in the Pathogenesis of Atrial Fibrillation.Front Cardiovasc Med. 2021 Feb 26;8:641136. doi: 10.3389/fcvm.2021.641136. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33718459 Free PMC article. Review.
-
Small heat shock proteins in redox metabolism: implications for cardiovascular diseases.Int J Biochem Cell Biol. 2012 Oct;44(10):1632-45. doi: 10.1016/j.biocel.2012.06.006. Epub 2012 Jun 15. Int J Biochem Cell Biol. 2012. PMID: 22710345 Free PMC article. Review.
-
Paroxysmal atrial fibrillation and hemochromatosis: a narrative review.Ann Med Surg (Lond). 2023 Dec 4;86(2):909-919. doi: 10.1097/MS9.0000000000001605. eCollection 2024 Feb. Ann Med Surg (Lond). 2023. PMID: 38333328 Free PMC article. Review.
-
Cardiac-specific knockdown of Bhlhe40 attenuates angiotensin II (Ang II)-Induced atrial fibrillation in mice.Front Cardiovasc Med. 2022 Oct 11;9:957903. doi: 10.3389/fcvm.2022.957903. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36304536 Free PMC article.
-
The immunoproteasome subunit LMP10 mediates angiotensin II-induced retinopathy in mice.Redox Biol. 2018 Jun;16:129-138. doi: 10.1016/j.redox.2018.02.022. Epub 2018 Mar 1. Redox Biol. 2018. PMID: 29499566 Free PMC article.
References
-
- Akar FG. Spragg DD. Tunin RS. Kass DA. Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res. 2004;95:717–725. - PubMed
-
- Allessie M. Ausma J. Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230–246. - PubMed
-
- Alsheikh–Ali AA. Wang PJ. Rand W. Konstam MA. Homoud MK. Link MS. Estes NA., III Salem DN. Al Ahmad AM. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J. 2004;147:1061–1065. - PubMed
-
- Blitzer M. Costeas C. Kassotis J. Reiffel JA. Rhythm management in atrial fibrillation–with a primary emphasis on pharmacological therapy: Part 1. Pacing Clin Electrophysiol. 1998;21:590–602. - PubMed
-
- Boldt A. Wetzel U. Weigl J. Garbade J. Lauschke J. Hindricks G. Kottkamp H. Gummert JF. Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol. 2003;42:1785–1792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical